At a glance
ClinicalIndex Comparison Record- ✓Histologically proven CD20+ low-grade B-cell lymphoma including follicular, marginal zone, monocytoid B-cell, and lymphoplasmacytoid lymphoma; previously untreated or in relapse
- ✓Measurable disease with clearly defined margins: ≥20 mm by conventional CT/MRI or ≥10 mm by spiral CT, or direct measurement for cutaneous lymphomas
- ✓Karnofsky performance score ≥70%
- ✓Adequate renal function: serum creatinine ≤2.5 mg/dL
- ✕Rituximab therapy within 6 months prior to entry
- ✕Systemic steroid therapy within 1 month prior to entry
- ✕Intermediate or high-grade NHL, mantle cell lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma
- ✕Active CNS disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rituximab and Dexamethasone in CD20 Positive Low Grade and Follicular Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating pharmacological study, rituximab, and 2 other interventions for Contiguous Stage II Grade 1 Follicular Lymphoma and 22 related conditions. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This phase II trial studies the side effects and how well giving rituximab and dexamethasone together works in treating patients with low-grade non-Hodgkin lymphoma (NHL). Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with dexamethasone may kill more cancer cells
Study Details
Timeline
Interventions
Correlative studies
Given IV
Given IV
Correlative studies